StreetInsider.com News Articles

Totaligent Announces Featured Speaking Role at U.S.–Taiwan Innovation Forum, Advancing Global Biologics and Medical Tourism Collaboration

Mon, 08 Jun 2026 08:05:00 -0400

BOCA RATON, Fla., June 08, 2026 (GLOBE NEWSWIRE) -- Totaligent, Inc. (OTCID: TGNT) (“Totaligent” or “the Company”), an emerging leader in specialized infrastructure for the biologics space and intelligent business marketing data, today highlighted the participation of Ivan Klarich, President and Board Member of Totaligent and founder of the Aetherium Medical platform, at the Uncharted Impact x A-Team Hub Accelerator. This prestigious U.S.–Taiwan innovation forum was hosted at Warner Brothers Studios in Burbank, California.

The event convened global investors, government representatives, startup leaders, and innovation ecosystem participants to drive cross-border collaboration and accelerate high-impact technologies. Klarich delivered

Totaligent Announces Featured Speaking Role at U.S.–Taiwan Innovation Forum, Advancing Global Biologics and Medical Tourism Collaboration

Mon, 08 Jun 2026 08:05:00 -0400

Totaligent Announces Featured Speaking Role at U.S.–Taiwan Innovation Forum, Advancing Global Biologics and Medical Tourism Collaboration

Mon, 08 Jun 2026 08:05:00 -0400

Totaligent Announces Featured Speaking Role at U.S.–Taiwan Innovation Forum, Advancing Global Biologics and Medical Tourism Collaboration

Mon, 08 Jun 2026 08:05:00 -0400

Totaligent forms joint venture with GloMed for Japan biologics market

Thu, 28 May 2026 08:05:08 -0400

Totaligent Inc. (OTCID: TGNT) announced the formation of a 50/50 joint venture between its subsidiary Aetherium Medical LLC and GloMed Solutions Limited Liability Company, effective May 22, 2026.

The joint venture combines Aetherium's medical platform with GloMed's distribution network, which includes relationships with over 20 key opinion leaders and specialty clinics across Asia-Pacific markets. The partnership aims to commercialize advanced biologics and medical devices in Japan and the broader APAC region through medical tourism channels.

"This joint venture represents a major milestone in Totaligent's strategy to become a leader at the intersection of innovative biologics and medical tourism," said Ivan Klarich, President

Totaligent forms joint venture with GloMed for Japan biologics market

Thu, 28 May 2026 08:05:08 -0400

Totaligent Inc. (OTCID: TGNT) announced the formation of a 50/50 joint venture between its subsidiary Aetherium Medical LLC and GloMed Solutions Limited Liability Company, effective May 22, 2026.

"This joint venture represents a major milestone in Totaligent's strategy to become a leader at the intersection of innovative biologics and medical tourism," said Ivan Klarich, President

Totaligent Announces Formation of Joint Venture with GloMed Solutions to Commercialize Advanced Biologics in Japan and APAC

Thu, 28 May 2026 08:05:00 -0400

BOCA RATON, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Totaligent, Inc. (OTCID: TGNT) (“Totaligent” or “the Company”), today announced the formation of a 50/50 joint venture between its wholly owned subsidiary, Aetherium Medical LLC, and GloMed Solutions Limited Liability Company (“GloMed”), a Japanese company with a proven distribution network in the Asia-Pacific region.

The Joint Venture, effective May 22, 2026, integrates Aetherium’s proprietary medical platform—including its dual-track regulatory strategy, intellectual property, know-how, and commercialization infrastructure—with GloMed’s established distribution infrastructure, which includes relationships with over 20 key opinion leaders and specialty clinics across high-growth APAC markets. The combined

Totaligent Announces Formation of Joint Venture with GloMed Solutions to Commercialize Advanced Biologics in Japan and APAC

Thu, 28 May 2026 08:05:00 -0400

Totaligent Announces Formation of Joint Venture with GloMed Solutions to Commercialize Advanced Biologics in Japan and APAC

Thu, 28 May 2026 08:05:00 -0400

Totaligent Announces Formation of Joint Venture with GloMed Solutions to Commercialize Advanced Biologics in Japan and APAC

Thu, 28 May 2026 08:05:00 -0400

Totaligent Closes Strategic Acqui-Hire of Aetherium Medical Platform

Wed, 20 May 2026 08:05:00 -0400

BOCA RATON, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- Totaligent, Inc. (OTCID: TGNT) (“Totaligent” or “the Company”), an emerging leader in specialized infrastructure platform for the blossoming biologics space and intelligent business marketing data, today announced the successful closing of the previously announced Definitive Agreement with Ivan Klarich, founder of Aetherium Medical, for the strategic acqui-hire of the Aetherium Medical platform and team.

The transaction, which was executed via Definitive Agreement on April 15, 2026, provides Totaligent with full ownership and immediate operational access to Aetherium’s proprietary business plan, trade secrets, know-how, network contacts, operational

Totaligent Closes Strategic Acqui-Hire of Aetherium Medical Platform

Wed, 20 May 2026 08:05:00 -0400

Totaligent Closes Strategic Acqui-Hire of Aetherium Medical Platform

Wed, 20 May 2026 08:05:00 -0400

Totaligent Closes Strategic Acqui-Hire of Aetherium Medical Platform

Wed, 20 May 2026 08:05:00 -0400

Form 10-Q Totaligent, Inc. For: Mar 31

Fri, 15 May 2026 10:16:00 -0400

si-local-file:///var/storage/secattach/20260515/26501422.html

Form 10-Q Totaligent, Inc. For: Mar 31

Fri, 15 May 2026 10:16:00 -0400

si-local-file:///var/storage/secattach/20260515/26501422.html

Totaligent Enters APAC Medical Tourism Market at Historic Inflection Point, as Global Healthcare Travel Surges Toward $274 Billion